scholarly journals Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

2008 ◽  
Vol 14 (9) ◽  
pp. 1017-1021 ◽  
Author(s):  
John E. Levine ◽  
Bruce R. Blazar ◽  
Todd DeFor ◽  
James L.M. Ferrara ◽  
Daniel J. Weisdorf
Keyword(s):  
Phase I ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Controlled Trial ◽  
Graft Versus Host ◽  
Long Term Follow Up ◽  
Related Donor

Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4383-4383
Author(s):  
Jonathan E. Benjamin ◽  
Ginna G. Laport ◽  
Laura J. Johnston ◽  
Sally Arai ◽  
Wen-Kai Weng ◽  
...  
Keyword(s):  
High Risk ◽  
Graft Versus Host Disease ◽  
Hematopoietic Cell Transplantation ◽  
Conditioning Regimen ◽  
Free Survival ◽  
Host Disease ◽  
Graft Versus Host ◽  
Related Donor

Abstract Patients with high-risk hematolymphoid malignancies who relapse or who do not achieve a complete remission to induction chemotherapy generally do not achieve long-term survival when treated with the best available non-transplant therapies. The benefit of allogeneic hematopoietic cell transplantation has been well described for patients in first complete remission, but less so for patients with advanced disease. We report the long-term follow-up of 131 patients with leukemia or lymphoma who received an HLA-matched related donor transplant following myeloablative conditioning with fractionated total body irradiation (1320cGy), etoposide (60mg/kg), and cyclophosphamide (60mg/kg). Eligibility for transplantation under this protocol included induction failure or high-risk disease that was beyond first remission. All patients were treated at a single institution. Diagnosis at the time of transplantation included ALL (n=57), AML (n=38), NHL (n=20), CML (n=10), MDS (4), JMML (n=2). Of the 95 patients with acute leukemia, 62 (65%) were not in remission at the commencement of the conditioning regimen. The median age at transplantation was 29 years (range 2–55). Seventy-four (56%) patients received unmanipulated bone marrow and the remainder received filgrastim-mobilized peripheral blood. Median follow-up of surviving patients was 8 years (range 0.3–17). The estimated five-year overall survival and event-free survival were 34% (95% confidence interval: 22–42%) and 32% (95% confidence interval: 24–39%), respectively. Leading causes of death included relapse (n=43), infection (n=11), acute graft-versus-host disease (n=8), respiratory failure (n=5) and hepatic veno-occlusive disease (n=4). Grade II–IV acute graft-versus-host disease occurred in 26% of patients. The cumulative incidence of extensive chronic graft-versus-host disease among those patients who survived beyond day 100 was 32%. These results indicate that patients with high-risk or advanced disease can experience long-term disease-free survival following an aggressive conditioning regimen that combines radiotherapy, etoposide, and cyclophosphamide. Relapse remains the most significant cause of mortality, and future efforts should focus on augmenting the graft-versus-malignancy effect.

scholarly journals Remote long-term follow-up clinic after hematopoietic cell transplantation using internet telemedicine: a single-institute experience

2021 ◽  
Vol 10 (2) ◽  
pp. 113-117
Author(s):  
Toshiki Mushino ◽  
Akinori Nishikawa ◽  
Yoshikazu Hori ◽  
Hideki Kosako ◽  
Yuichi Tochino ◽  
...  
Keyword(s):  
Cell Transplantation ◽  
Hematopoietic Cell Transplantation ◽  
Hematopoietic Cell ◽  
Long Term Follow Up

scholarly journals Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial

Blood ◽  
1989 ◽  
Vol 73 (6) ◽  
pp. 1729-1734 ◽  
Author(s):  
R Storb ◽  
HJ Deeg ◽  
M Pepe ◽  
F Appelbaum ◽  
C Anasetti ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Controlled Trial ◽  
Chronic Gvhd ◽  
Host Disease ◽  
Graft Versus Host ◽  
Myelocytic Leukemia ◽  
Long Term Follow Up ◽  
Early Survival ◽  
Marrow Infusion

Abstract Patients with acute nonlymphoblastic leukemia (ANL) in first remission (n = 38) or chronic myelocytic leukemia (CML) (n = 55) were given cyclophosphamide and total body irradiation, followed by marrow infusion from HLA-identical siblings. To evaluate postgrafting prophylaxis for acute graft-versus-host disease (GVHD), the patients were randomized to receive either methotrexate and cyclosporine (n = 43) or cyclosporine alone (n = 50). Methotrexate/cyclosporine significantly reduced the incidence and severity of acute GVHD, and improved early survival. This report updates the results with a 3.0 to 4.5 year follow-up. Methotrexate/cyclosporine did not interfere with sustained hematopoietic engraftment, although granulocyte recovery to 1,000/microL was delayed by five days on the average. The incidence of chronic GVHD was identical in the two groups (26% v 24%). Disease-free 3-year survival was slightly better in the methotrexate/cyclosporine group (65% v 54%), but this benefit was restricted to patients with CML (73% v 54%), while no improvement was seen in patients with ANL (41% v 41%). In contrast to patients with CML (relapse rates 8% v 9%), the early survival benefit among patients with ANL given methotrexate/cyclosporine was offset by an increase in leukemic relapses (29% v 16%).

Sign in / Sign up

Export Citation Format

Share Document